Long-term outcomes in patients after discontinuation of PD1/PDL1 inhibitors.
2018
e15086Background: PD1/PDL1inhibitors have been approved for several advanced or metastatic malignancies with improvement in both progression free and overall survival. Yet, there is a paucity of da...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI